Amgen's Imdelltra with AstraZeneca immunotherapy reduces lung cancer death risk by 58%

A new combination treatment involving Amgen's Imdelltra and an immunotherapy from AstraZeneca has shown to reduce the risk of death by 58% in patients with an aggressive form of lung cancer. This development could significantly extend survival times for affected patients.

Originally published by gnews